There are hedge fund managers who invest exclusively in one particular industry. For Jacob Gottlieb of New York City, owner of the hedge fund management firm Altium Capital, that industry is healthcare. He has a college degree and interned as a medical doctor so investing in healthcare firms was right up his alley. He primarily invests in small to mid-cap sized healthcare companies that have innovative products not available through anyone else.
He just started this company in June 2018. The first investment Jacob Gottlieb made was in Oramed Pharmaceuticals. Purchasing a 5.61 percent stake, he is highly confident in their FDA approved products which includes their orally ingestible insulin capsule. A oral treatment for diabetics has been a long-pursued goal for many pharmaceutical firms.
Dublin, Ireland’s Amarin was Jacob Gottlieb’s second investment. He sees a great deal of promise in the drugs they are developing to help people improve their cardiovascular health. This company had their first FDA-approved Drug, Vascepa, approved for use six years ago.
Jacob Gottlieb has been working as a professional investor since 1998. He started out as a researcher at small hedge fund management firm, Sanford C. Bernstein, LLC. He was hired to provide his investment guidance for investing in healthcare firms all over the globe. Two years later he joined Merlin where he was one of their portfolio managers and proved himself to be highly skilled in this position.
He became an entrepreneur the following year. Jacob Gottlieb co-founded Balyasny Asset Mangement where he was their top earning portfolio manager. In 2005, he founded Visium Asset Management. This company hit its peak in 2016 when it was managing $8 billion in assets, all invested in healthcare firms. He had to close this company, though, after other people engaged in insider trading which unfortunately impacted his company.